Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QZUFE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BL-B16D1
|
|||||
| Synonyms |
BL-B16D1; BL B16D1; BLB16D1
Click to Show/Hide
|
|||||
| Organization |
Sichuan Baili Pharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 3 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Receptor tyrosine-protein kinase erbB-3 (HER3)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
